Hikal Limited (NSE:HIKAL)
241.85
+1.95 (0.81%)
Oct 29, 2025, 3:30 PM IST
Hikal Revenue
Hikal had revenue of 3.80B INR in the quarter ending June 30, 2025, a decrease of -6.49%. This brings the company's revenue in the last twelve months to 18.33B, up 1.66% year-over-year. In the fiscal year ending March 31, 2025, Hikal had annual revenue of 18.60B with 4.21% growth.
Revenue (ttm)
18.33B
Revenue Growth
+1.66%
P/S Ratio
1.62
Revenue / Employee
8.89M
Employees
2,062
Market Cap
29.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 18.60B | 752.00M | 4.21% |
| Mar 31, 2024 | 17.85B | -2.38B | -11.79% |
| Mar 31, 2023 | 20.23B | 803.09M | 4.13% |
| Mar 31, 2022 | 19.43B | 2.22B | 12.92% |
| Mar 31, 2021 | 17.20B | 2.13B | 14.14% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Hikal News
- 5 weeks ago - Baba Kalyani's son retains Hikal board seat amid feud - The Times of India
- 2 months ago - Hikal shares fall over 2% after US FDA issues warning letter for Jigani facility - Business Upturn
- 2 months ago - Hikal receives warning letter from US FDA for Jigani facility - Business Upturn
- 2 months ago - Hikal shares fall nearly 7% after Q1 loss of Rs 22.4 crore - Business Upturn
- 2 months ago - Hikal reports Q1 net loss of Rs 22.4 crore; revenue declines 6.5% YoY - Business Upturn
- 4 months ago - Hikal successfully clears ANVISA GMP audit for Bengaluru API manufacturing facility - Business Upturn
- 5 months ago - Hikal receives OAI classification from US FDA for Jigani facility - Business Upturn
- 6 months ago - Hikal share price jumps 4% as Q4 revenue rises 7.4% YoY to Rs 552 crore, net profit up 48% YoY - Business Upturn